Open an Account
search icon
2
NOTIFICATIONS
Best Algo trading app in India
Bigul

CHEMO PHARMA LABORATORIES LTD. - 506365 - Announcement under Regulation 30 (LODR)-Change in Directorate

 Dear Sirs, This is to inform you that pursuant to Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we wish to inform you following matters- 1. The Board of Directors in its meeting held on Thursday, 28th January, 2021 at 04 p.m. at the Corporate Office of the Company appointed Shri. Bhavin Sheth as an Additional Director of the Company in the Category of Executive Director. 2. The Board of Directors in its meeting held on Thursday, 28th January, 2021 at 04 p.m. at the Corporate Office of the Company appointed Shri. Bhavin Sheth also as Chief Executive Officer of the Company. This is for your kind records and reference.
29-01-2021
Bigul

CHEMO PHARMA LABORATORIES LTD. - 506365 - Revised Outcome For The Board Meeting Held On 28.01.2021

 Revised outcome for the Board Meeting held on 28.01.2021 - Dear Sir, We would like to inform you that the Board of Directors in its Meeting held on Thursday, 28th January, 2021 at 04:00 p.m. at the Corporate Office of the Company at 3rd Floor, Empire House, 214, Dr. D. N. Road, Fort, Mumbai - 400001, inter-alia took the following decisions: 1.Considered and approved Un-Audited Financial Results as recommended by the Audit Committee for the Quarter ended 31st December, 2020. 2.Placed and took on record the Limited Review Report issued by the Statutory Auditor of the Company based on Un-Audited Financial Results for the Quarter ended 31st December, 2020. 3.Considered and appointed Shri. Bhavin Sheth as an Additional Director of the Company. 4.Considered and appointed Shri. Bhavin Sheth as Chief Executive Officer (CEO) of the Company.
28-01-2021
Bigul

CHEMO PHARMA LABORATORIES LTD. - 506365 - Submission Of Un-Audited Financial Results For The Quarter Ended 31.12.2020

 Submission of Un-Audited Financial Results for the quarter ended 31.12.2020
28-01-2021
Bigul

CHEMO PHARMA LABORATORIES LTD. - 506365 - Outcome Of Board Meeting

 Dear Sir, We would like to inform you that the Board of Directors in its Meeting held on Thursday, 28th January, 2021 at 04:00 p.m. at the Corporate Office of the Company at 3rd Floor, Empire House, 214, Dr. D. N. Road, Fort, Mumbai - 400001, inter-alia took the following decisions: 1.Considered and approved Un-Audited Financial Results as recommended by the Audit Committee for the Quarter ended 31st December, 2020. 2.Placed and took on record the Limited Review Report issued by the Statutory Auditor of the Company based on Un-Audited Financial Results for the Quarter ended 31st December, 2020.
28-01-2021
Bigul

CHEMO PHARMA LABORATORIES LTD. - 506365 - Board Meeting Intimation for Intimation Of Board Meeting To Be Held Thursday, 28Th January, 2021

 CHEMO PHARMA LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2021 ,inter alia, to consider and approve Dear Sir, This is to inform you that the Meeting of the Board of Directors of the Company will be held on Thursday, 28th January, 2021 at 04:00 p.m. at the Corporate Office of the Company at Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400001 to transact the following business: 1.To consider and approve the Un-Audited Financial Results for the Quarter ended 31st December, 2020. 2.To place and take on record the Limited Review Report on Un-Audited Financial Results for the quarter ended 31st December, 2020. 3.To consider and appoint Shri. Bhavin Sheth as an Additional Director of the Company. 4.To consider and appoint Shri. Bhavin Sheth as Chief Executive Officer (CEO) of the Company.
12-01-2021
Bigul

CHEMO PHARMA LABORATORIES LTD. - 506365 - Shareholding for the Period Ended December 31, 2020

 Chemo Pharma Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2020. For more details, kindly Click here
11-01-2021
Bigul

CHEMO PHARMA LABORATORIES LTD. - 506365 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Shreeniwas Somani & Shanta Somani
05-01-2021
Bigul

CHEMO PHARMA LABORATORIES LTD. - 506365 - Statement Of Investor Complaints For The Quarter Ended December 2020

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 1001 Name of the Signatory :- Ashok SomaniDesignation :- Chief Financial Officer
04-01-2021
Bigul

CHEMO PHARMA LABORATORIES LTD. - 506365 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Submission of Certificate pursuant to Regulation 74(5) for the period from 01/10/2020 to 31/12/2020
04-01-2021
Bigul

CHEMO PHARMA LABORATORIES LTD. - 506365 - Closure of Trading Window

 Intimation of Closure of Trading Window for the quarter ended 31.12.2020
30-12-2020
Next Page
Close

Let's Open Free Demat Account